Ultragenyx says Phase 3 Aspire missed primary, key secondary endpoints
Ultragenyx said Phase 3 Aspire of apazunersen in Angelman syndrome failed to meet its primary and key secondary endpoints.
Ultragenyx announced that the Phase 3 Aspire study of apazunersen in Angelman syndrome failed to meet its primary and key secondary endpoints.Key Highlights:Original SEC Filing: Ultragenyx Pharmaceutical Inc. [ RARE ] - 8-K - Sep.
02, 2026This is an AI-powered summary.
It may contain inaccuracies…